Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Nursing Standard (Royal College of Nursing (Great Britain) : 1987)|May 7, 2015
Documentation and record-keeping in pressure ulcer managementEdwin Chamanga, Renee Ward
The Journal of Molecular Diagnostics : JMD|August 11, 2007
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanomaCynthia Spittle, M Renee Ward, Katherine L Nathanson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemiaGuillermo Garcia-Manero, Steven D Gore, Christopher Cogle, et al.
Cancer Research|September 6, 2005
Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridizationGöran Jönsson, Tara L Naylor, Johan Vallon-Christersson, et al.
Clinical Breast Cancer|June 27, 2007
Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United StatesJulia Tchou, M Renee Ward, Patricia Volpe, et al.
Cancer Research|February 12, 2005
Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growthLin Zhang, Nuo Yang, Jia Huang, et al.
Genes, Chromosomes & Cancer|May 13, 2011
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcomeJia Huang, Lin Zhang, Joel Greshock, et al.
The Lancet. Oncology|October 29, 2011
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trialAnas Younes, Yasuhiro Oki, R Gregory Bociek, et al.
Haematologica|July 22, 2017
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndromeNaval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Pageof 1